iBio Highlights Data from a Non-human Primate Study Supporting IBIO-610’s Potential to Preserve Muscle in Combination with GLP-1 Therapy
iBio reported body-composition results from an eight-week obese non-human primate study of IBIO-610, an Activin E antibody, alone and with semaglutide; company data show a smaller share of lean mass loss when IBIO-610 is combined with semaglutide and describe pharmacokinetic and biomarker findings supporting a first-in-human study planned for the first half of 2027.